Under construction – not a live service

Skip to content

Frontlight Research

Institution

Hospices Civils de Lyon

Lyon, FrancehealthcareWebsite

Also known as: HCL

597running trials
205closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Not yet recruiting
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562· Phase 3· Source
Not yet recruiting
A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.
2026-525162-21-00· Phase 2· Source
Not yet recruiting
Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis
NCT07718529· Phase 4· Source
Not yet recruiting
Inhaled Hydrogen Therapy's Effect on Early Recurrences of Atrial Fibrillation Post-ablation.
NCT07928622· Phase 2· Source
Not yet recruiting
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
NCT07738887· Phase 2· Source
Not yet recruiting
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· Phase 3· Source
Not yet recruiting
Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis
2025-523400-72-00· Phase 2· Source
Not yet recruiting
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
NCT07612787· Phase 1/2· Source
Not yet recruiting
Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT07739459· Phase 2· Source
Not yet recruiting
Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial
NCT07915037· Phase 3· Source
Not yet recruiting
A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis
2026-526404-71-00· Phase 2· Source
Not yet recruiting
Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose
NCT07700446· Phase 4· Source
Recruiting
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
NCT07781657· Phase 2· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· Phase 3· Source
Recruiting
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
NCT07629583· Phase 1· Source
Not yet recruiting
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· Phase 3· Source
Not yet recruiting
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
NCT07759492· Phase 2· Source
Not yet recruiting
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
2025-522019-40-00· Phase 1/2· Source
Not yet recruiting
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
NCT07503340· Phase 2· Source
Not yet recruiting
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
NCT07929740· Phase 1· Source
Recruiting
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
2025-524641-27-00· Phase 3· Source
Not yet recruiting
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial
NCT07818356· Phase 4· Source
Recruiting
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
NCT07830732· Phase 3· Source
Not yet recruiting
Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in Adults Living With Type 1 Diabetes
NCT07401901· Source
Not yet recruiting
A clinical trial to learn more about the effects of DJI136 in people with extensive-stage small cell lung cancer
2025-523276-23-00· Phase 1/2· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· Phase 3· Source
Recruiting
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.
2025-525030-57-00· Phase 3· Source
Recruiting
Impact of Epilepsy on the Brainstem Adenosine Pathway and Its Relation With Arousal and Respiratory Reactivity
NCT07249034· Source
Not yet recruiting
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00· Phase 3· Source
Not yet recruiting
Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA
2026-525463-40-00· Phase 1/2· Source
Not yet recruiting
Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.
NCT07717450· Phase 3· Source
Recruiting
A study to evaluate safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-NHL
2025-524915-36-00· Phase 1/2· Source
Recruiting
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· Phase 3· Source
Recruiting
ROSY-F: Roll-over Study for Participants Who Have Completed a Previous Clinical Study with Benralizumab (Fasenra) and Benefit from Continued Treatment
2025-523307-29-00· Phase 3· Source
Recruiting
Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
2026-525489-23-00· Phase 3· Source
Recruiting
Evaluating Aganirsen Eye Drops to Reduce the Number of Aflibercept Injections in Wet Age-Related Macular Degeneration Patients.
2026-526775-27-00· Phase 2· Source
Not yet recruiting
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
NCT07420439· Phase 2· Source
Recruiting
Feasibility of the Application of a new Six-month Treatment for multidrug-resistant tuberculosis (MDR-TB) patients in France (FAST-MDR)
2024-512763-32-00· Phase 3· Source
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Source
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790· Phase 3· Source
Recruiting
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
2025-523285-25-00· Phase 3· Source
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
2025-525016-41-00· Phase 2· Source
Not yet recruiting
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
NCT07721363· Phase 2· Source
Not yet recruiting
Cardiorenal Syndrome: Characteristics and Prognostic Impact in Advanced Heart Failure
NCT07666516· Source
Recruiting
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· Phase 3· Source
Not yet recruiting
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2
2026-525759-96-00· Phase 4· Source
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117· Phase 3· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· Source
Recruiting
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
NCT07566052· Phase 3· Source
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Researchers

No researcher is linked here yet.

Closed trials

Recruiting
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
NCT07564141· Phase 3· Source
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843· Phase 1· Source
Completed
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease
2024-516966-12-00· Phase 2· Source
Recruiting
A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B
NCT07200193· Phase 1/2· Source
Completed
Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)
NCT06984328· Phase 2· Source
Completed
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.
2024-519258-35-00· Phase 2· Source
Completed
GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.
2025-521107-42-00· Phase 2· Source
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· Phase 3· Source
Recruiting
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
NCT07220564· Phase 1· Source
Completed
Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection
2024-519856-94-00· Phase 2· Source
Recruiting
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849· Phase 2· Source
Completed
A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status
2024-511239-91-00· Phase 2· Source
Active, not recruiting
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567· Phase 1/2· Source
Completed
Smart MDI Study (CIP343)
NCT06645834· Source
Active, not recruiting
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
NCT06444113· Phase 4· Source
Completed
Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE
NCT06425159· Phase 2/3· Source
Completed
A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment
2023-509027-41-00· Phase 1· Source
Active, not recruiting
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768· Phase 1/2· Source
Completed
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219· Phase 2· Source
Completed
ALS Phase II Study of NX210c
NCT06365216· Phase 2· Source
Recruiting
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
NCT06333808· Phase 3· Source
Completed
A Clinical Study of Mitapivat in Patients with Sickle Cell Disease and Kidney Disease
NCT06286046· Phase 2· Source
Active, not recruiting
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027· Phase 3· Source
Completed
Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France
NCT06735781· Source
Completed
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT06335303· Phase 2· Source
Completed
A study to see how safe and effective the drug Luveltamab Tazevibulin (STRO-002) is in treating infants and children under 12 years old with a specific type of acute myeloid leukemia (AML)
2023-506240-16-00· Phase 1/2· Source
Active, not recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534· Phase 3· Source
Completed
Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trial
NCT04667078· Phase 4· Source
Completed
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
2023-506185-31-00· Phase 2/3· Source
Active, not recruiting
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
NCT06483334· Phase 1/2· Source
Completed
A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
NCT06450366· Phase 3· Source
Completed
A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis
NCT06478706· Phase 2· Source
Completed
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
NCT06388187· Phase 3· Source
Active, not recruiting
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06223516· Phase 1· Source
Completed
A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
2023-507207-66-00· Phase 3· Source
Completed
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis
2023-506655-19-00· Phase 2· Source
Completed
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE
NCT06079190· Phase 2· Source
Completed
Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy
2023-509615-92-00· Phase 2· Source
Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067· Phase 3· Source
Completed
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
NCT05813288· Phase 3· Source
Completed
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928· Phase 2· Source
Completed
A proof of concept and dose-finding study of XXB750 in patients with heart failure
2023-504678-39-00· Phase 2· Source
Completed
A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)
2023-509472-42-00· Phase 3· Source
Recruiting
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
NCT06239311· Phase 3· Source
Completed
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis
2022-502997-18-00· Phase 1· Source
Active, not recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163· Phase 3· Source
Completed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
NCT06224348· Phase 3· Source
Active, not recruiting
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
NCT05970172· Phase 3· Source
Completed
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306· Phase 3· Source
Completed
A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma
NCT06018129· Phase 1/2· Source

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 01502ca60 (CC0-1.0)Updated 10 Nov 2026

Report an error

Under construction, not live – Hospices Civils de Lyon: trials and research groups – Frontlight Research